AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Clinical Outcomes of Exenatide Versus Basal Insulin
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18000
- Registration Number
- NCT02987348
- Locations
- 🇬🇧
Pharmatelligence, Cardiff, United Kingdom
FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study
- Conditions
- Ovarian Cancer
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 471
- Registration Number
- NCT02984423
- Locations
- 🇵🇪
Research Site, San Isidro, Peru
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
- Conditions
- Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 272
- Registration Number
- NCT02983799
- Locations
- 🇨🇦
Research Site, Sherbrooke, Quebec, Canada
A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies
- Conditions
- Advanced Malignancy
- Interventions
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26
- Registration Number
- NCT02978482
- Locations
- 🇨🇳
Research Site, Changchun, China
Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 83
- Registration Number
- NCT02976831
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7000
- Registration Number
- NCT02974244
- Locations
- 🇺🇸
Optum Epidemiology, Boston, Massachusetts, United States
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 421
- Registration Number
- NCT02972658
- Locations
- 🇺🇸
Brain Matters Research, Delray Beach, Florida, United States
🇺🇸IMIC, Inc., Palmetto Bay, Florida, United States
🇺🇸Suncoast Neuroscience Associates, Saint Petersburg, Florida, United States
Study With Dapagliflozin
- Conditions
- Diabetes Mellitus Type 2
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 929
- Registration Number
- NCT02971618
- Locations
- 🇷🇺
Research Site, Saint Petersburg, Russian Federation
Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871
- Conditions
- Chronic Obstructive Pulmonary Disease COPD
- Interventions
- Drug: AZD8871 100 µgDrug: PlaceboDrug: AZD8871 600 µg
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT02971293
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers
- Conditions
- AsthmaChronic Obstructive Pulmonary Disease
- Interventions
- Biological: Benralizumab
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT02968914
- Locations
- 🇩🇪
Research Site, Harrow, Germany